Scott Mikesell, DO
Cardiovascular Disease · Duluth, MNNPI 1881684942
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.6%), food and beverage and grants — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Edwards Lifesciences at 54.3% of the total.
Across 255 payments — averaging $47.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$7K
- Abiomed$3K
- Boston Scientific$2K
- Shockwave Medical, Inc$594
- Medtronic$390
- Abbott$101
- plus $12 from 1 others
Across 95 payments — averaging $1196.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$90K
- AstraZeneca$20K
- Philips North America LLC$4K
What the payments were for
- Grants$2402%
- Travel & lodging$6,30952%
- Food & beverage$5,60846%
- Education$751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 167 | $6,642 |
| Abiomed | 10 | $2,916 |
| Boston Scientific | 33 | $1,578 |
| Shockwave Medical, Inc | 24 | $594 |
| Medtronic | 17 | $390 |
| Abbott | 3 | $101 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,233 in reported general payments places this provider in the 75th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 93 | $91,725 |
| XareltoRivaroxaban | 35 | $37,646 |
| Repatha SureclickEvolocumab | 22 | $27,596 |
| Metoprolol Succinate | 215 | $4,758 |
| Atorvastatin Calcium | 117 | $1,896 |
| Rosuvastatin Calcium | 122 | $1,767 |
| Losartan Potassium | 135 | $1,353 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 99 | $1,280 |
| ClopidogrelClopidogrel Bisulfate | 123 | $1,276 |
| Amlodipine Besylate | 77 | $772 |
| Carvedilol | 116 | $771 |
| Metoprolol Tartrate | 65 | $597 |
| Potassium Chloride | 25 | $569 |
| Ezetimibe | 32 | $437 |
| Lisinopril | 44 | $390 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Duluth
- Christopher LatanichDuluth$128K
- Graham LohrmannDuluth$47K
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Nedaa SkeikMinneapolis$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.